These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28848921)

  • 21. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
    Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
    Donohue JF; Jones PW; Bartels C; Marvel J; D'Andrea P; Banerji D; Morris DG; Patalano F; Fogel R
    Pulm Pharmacol Ther; 2018 Apr; 49():11-19. PubMed ID: 29277690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life measured by the St George's Respiratory Questionnaire and spirometry.
    Weatherall M; Marsh S; Shirtcliffe P; Williams M; Travers J; Beasley R
    Eur Respir J; 2009 May; 33(5):1025-30. PubMed ID: 19164350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American translation, modification, and validation of the St. George's Respiratory Questionnaire.
    Barr JT; Schumacher GE; Freeman S; LeMoine M; Bakst AW; Jones PW
    Clin Ther; 2000 Sep; 22(9):1121-45. PubMed ID: 11048909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting.
    Rutten-van Mölken M; Roos B; Van Noord JA
    Thorax; 1999 Nov; 54(11):995-1003. PubMed ID: 10525558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing health status over time: impact of recall period and anchor question on the minimal clinically important difference of copd health status tools.
    Alma HJ; de Jong C; Jelusic D; Wittmann M; Schuler M; Kollen BJ; Sanderman R; Schultz K; Kocks JWH; Van der Molen T
    Health Qual Life Outcomes; 2018 Jun; 16(1):130. PubMed ID: 29940980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.
    Mahler DA; Kerstjens HA; Donohue JF; Buhl R; Lawrence D; Altman P
    Respir Med; 2015 Aug; 109(8):1031-9. PubMed ID: 26094050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.
    Zayed Y; Barbarawi M; Kheiri B; Haykal T; Chahine A; Rashdan L; Hamid K; Sundus S; Banifadel M; Aburahma A; Bachuwa G; Chandran A
    Clin Respir J; 2019 Jul; 13(7):413-428. PubMed ID: 30947394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD?
    Morishita-Katsu M; Nishimura K; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Ogawa T; Watanabe F; Arizono S; Nishiyama O; Nakayasu K; Imaizumi K; Hasegawa Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1543-51. PubMed ID: 27462150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beclometasone for chronic obstructive pulmonary disease.
    De Coster DA; Jones M; Thakrar N
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009769. PubMed ID: 24105424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation and clinical interpretation of the St George's respiratory questionnaire for COPD (SGRQ-C) after adaptation to Malaysian language and culture, in patients with COPD.
    Rehman AU; Hassali MAA; Harun SN; Abbas S; Muneswarao J; Ali IABH; Hussain R
    Health Qual Life Outcomes; 2020 May; 18(1):138. PubMed ID: 32404113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW; Mahler DA; Gale R; Owen R; Kramer B
    Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
    Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
    Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.